Display options
Cite
Li Y, Cheng H, Zhang Z, et al. N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors. ACS Med Chem Lett. 2015;6(5):543-7doi: 10.1021/acsmedchemlett.5b00039.
Li, Y., Cheng, H., Zhang, Z., Zhuang, X., Luo, J., Long, H., Zhou, Y., Xu, Y., Taghipouran, R., Li, D., Patterson, A., Smaill, J., Tu, Z., Wu, D., Ren, X., & Ding, K. (2015). N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors. ACS medicinal chemistry letters, 6(5), 543-7. https://doi.org/10.1021/acsmedchemlett.5b00039
Li, Yingjun, et al. "N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors." ACS medicinal chemistry letters vol. 6,5 (2015): 543-7. doi: https://doi.org/10.1021/acsmedchemlett.5b00039
Li Y, Cheng H, Zhang Z, Zhuang X, Luo J, Long H, Zhou Y, Xu Y, Taghipouran R, Li D, Patterson A, Smaill J, Tu Z, Wu D, Ren X, Ding K. N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors. ACS Med Chem Lett. 2015 Mar 18;6(5):543-7. doi: 10.1021/acsmedchemlett.5b00039. eCollection 2015 May 14. PMID: 26005530; PMCID: PMC4434482.
Copy Download .nbib Format: NLM
Share it on

ACS Med Chem Lett. 2015 Mar 18;6(5):543-7. doi: 10.1021/acsmedchemlett.5b00039. eCollection 2015 May 14.

N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors.

ACS medicinal chemistry letters

Yingjun Li, Huimin Cheng, Zhang Zhang, Xiaoxi Zhuang, Jinfeng Luo, Huoyou Long, Yang Zhou, Yong Xu, Rana Taghipouran, Dan Li, Adam Patterson, Jeff Smaill, Zhengchao Tu, Donghai Wu, Xiaomei Ren, Ke Ding

Affiliations

  1. State Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences , #190 Kaiyuan Avenue, Guangzhou 510530, China ; University of Chinese Academy of Sciences , #19 Yuquan Road, Beijing 100049, China.
  2. State Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences , #190 Kaiyuan Avenue, Guangzhou 510530, China.
  3. State Key Laboratory of Respiratory Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences , #190 Kaiyuan Avenue, Guangzhou 510530, China ; Biotechnological Institute of Chinese Materia Medica and Department of Pharmacology, Jinan University , #601 Huangpu Avenue West, Guangzhou 510632, China.
  4. Auckland Cancer Society Research Centre and Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland , #92019 Private Bag, Auckland 1142, New Zealand.
  5. Auckland Cancer Society Research Centre and Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland , #92019 Private Bag, Auckland 1142, New Zealand ; Auckland Cancer Society Research Centre and Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland , #92019 Private Bag, Auckland 1142, New Zealand.

PMID: 26005530 PMCID: PMC4434482 DOI: 10.1021/acsmedchemlett.5b00039

Abstract

A series of N-(3-ethynyl-2,4-difluorophenyl)sulfonamides were identified as new selective Raf inhibitors. The compounds potently inhibit B-Raf(V600E) with low nanomolar IC50 values and exhibit excellent target specificity in a selectivity profiling investigation against 468 kinases. They strongly suppress proliferation of a panel of human cancer cell lines and patient-derived melanoma cells with B-Raf(V600E) mutation while being significantly less potent to the cells with B-Raf(WT). The compounds also display favorable pharmacokinetic properties with a preferred example (3s) demonstrating significant in vivo antitumor efficacy in a xenograft mouse model of B-Raf(V600E) mutated Colo205 human colorectal cancer cells, supporting it as a promising lead compound for further anticancer drug discovery.

Keywords: B-Raf; colon cancer; kinase inhibitor; melanoma; targeted therapy

References

  1. Carcinogenesis. 2004 Apr;25(4):527-33 - PubMed
  2. Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14903-8 - PubMed
  3. N Engl J Med. 2011 Jun 16;364(24):2305-15 - PubMed
  4. N Engl J Med. 2012 Jan 19;366(3):207-15 - PubMed
  5. Nat Med. 2013 Nov;19(11):1401-9 - PubMed
  6. Endocr Relat Cancer. 2005 Jun;12(2):245-62 - PubMed
  7. Nat Biotechnol. 2008 Jan;26(1):127-32 - PubMed
  8. Oncogene. 2007 May 14;26(22):3279-90 - PubMed
  9. J Med Chem. 2012 Sep 13;55(17):7332-41 - PubMed
  10. Nat Rev Cancer. 2014 Jul;14(7):455-67 - PubMed
  11. Nature. 2010 Sep 30;467(7315):596-9 - PubMed
  12. J Med Chem. 2014 Mar 27;57(6):2692-703 - PubMed
  13. Cell. 2004 Mar 19;116(6):855-67 - PubMed
  14. Expert Opin Drug Metab Toxicol. 2013 Jul;9(7):893-9 - PubMed
  15. Oncogene. 2011 Aug 11;30(32):3477-88 - PubMed
  16. Pharmacol Ther. 2014 May;142(2):176-82 - PubMed
  17. Expert Opin Investig Drugs. 2013 Jun;22(6):739-49 - PubMed
  18. Front Genet. 2013 May 08;4:66 - PubMed

Publication Types